Business Wire

PIXIE-DUST-TECHNOLOGIES

20.12.2023 04:01:34 CET | Business Wire | Press release

Share
“Defy Dementia with Sound.” Pixie Dust Technologies, Shionogi and Shionogi Healthcare create Gamma Wave Sound to boost everyday cognitive care.

Pixie Dust Technologies, Inc., Shionogi & Co., Ltd, and Shionogi Healthcare Co., Ltd released “Memory” and “Tomorrow”, two audio experiences incorporating gamma wave technology1 designed to provide dementia patients with an additional tool that they can use to care for their cognitive function.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231219774481/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Gamma Wave Sound (Graphic: Business Wire)

It is estimated that every 3 seconds, someone develops dementia – a general term for a decline in mental ability severe enough to interfere with daily life. By 2050, more than 150 million people globally will live with dementia. Patients can preserve their quality of life and enhance overall wellness by engaging in activities that stimulate the brain.

Ongoing studies2345 demonstrate that repeated exposure to 40Hz gamma waves can promote brain function by reducing white matter atrophy and myelin loss, which contribute to Alzheimer’s disease progression. Data validated by Pixie Dust Technologies Inc. and Shionogi & Co., Ltd confirmed that gamma wave power and its entrainment increased when listening to amplitude-modulated 40Hz sounds, suggesting that such sounds can be clinically applied to dementia prevention as a non-invasive method.

The Dementia Care Project by Gamma Wave Sound is an initiative designed to help people care for their cognitive function through auditory stimulation. Turning gamma waves technology into a readily available audio experience presents new possibilities in providing cognitive stimulation for dementia.

Six major companies across industries in Japan have come together to form the alliance to boost dementia care as part of the Dementia Care Project by Gamma Wave Sound. These diverse companies share a common goal – to bring integrated daily care of cognitive function through its public touchpoints.

The number of participating companies continues to grow under the initiative, with gamma wave sound experience being brought to places where sound can be heard, such as the largest shopping malls and fitness gym’s exercising program, and local onsen resting spots in Japan.

Expanding to other countries as an international effort, Alii Palau Airlines, which provides direct flight service between Singapore and Palau, is playing both gamma wave audio tracks “Memory” and “Tomorrow”.

Furthermore, music artists who support the initiative have released the Gamma Wave Sound edit of their tracks, accelerating the efforts to deliver Gamma Wave Sound through entertainment.

The original soundtracks are available for download on YouTube (Memory (Gamma Wave Sound Edit) , Tomorrow (Gamma Wave Sound Edit)) , Spotify, Apple Music Podcast.

For more information, please visit our website at:  https://www.project.gammawavesound.com/home-1

References

1 Patent filed in Japan; patented technology processes audio by performing 40Hz amplitude modulation on partial signals included in input audio.
2 Martorell, A. J., Paulson, A. L., Suk, H. J., Abdurrob, F., Drummond, G. T., Guan, W., ... & Tsai, L. H. (2019). Multi-sensory gamma stimulation ameliorates Alzheimer’s-associated pathology and improves cognition. Cell, 177(2), 256-271.
3 Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease. (2023, June 17).
4 Business Wire: Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE
5-1 Business Wire: Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
5-2 2023 Association for Research in Otolaryngology Midwinter Meeting Abstract Book, pp.443-444 (2023).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231219774481/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye